Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The FIRE-3 trial investigated combination chemotherapy plus either cetuximab or bevacizumab in patients with untreated metastatic colorectal cancer (mCRC) not scheduled for upfront surgery. We aimed to determine the number of patients who present with potentially resectable disease during systemic first-line therapy and to compare the findings with study reports concerning resections and outcome.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur. J. Cancer

Title: European journal of cancer (Oxford, England : 1990)

Publisher: Elsevier BV

ISSN (Electronic): 1879-0852

ISSN (Print): 0959-8049

Publication date (Electronic): January 2018

Volume: 88

Affiliations

[1 ] Department of Medicine III, Hospital of the University of Munich (LMU), Munich, Germany; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany. Electronic address: dominik.modest@med.uni-muenchen.de.

[2 ] Institute of Radiology, Charité, Berlin, Germany.

[3 ] General, Visceral, and Transplantation Surgery, Charité - Universitätsmedizin Berlin, Berlin, Germany.

[4 ] Institute of Medical Informatics, Biometry and Epidemiology, University of Munich (LMU), Munich, Germany.

[5 ] Department of General, Abdominal and Transplantation Surgery, University Medical Center, Mainz, Germany.

[6 ] Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands.

[7 ] Department of General and Thoracic Surgery, University Hospital Schleswig-Holstein, Kiel, Germany.

[8 ] Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Hospital of the University of Munich, Munich, Germany.

[9 ] Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital Leipzig, Leipzig, Germany.

[10 ] Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany.

[11 ] German Aerospace Centre, Oberpfaffenhofen, Germany.

[12 ] ClinAssess GmbH, Leverkusen, Germany.

[13 ] University Cancer Center/Medical Department I, University Hospital Carl Gustav Carus, Dresden, Germany.

[14 ] Department of Medicine III, Hospital of the University of Munich (LMU), Munich, Germany; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany.

[15 ] Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of General, Visceral and Transplantation Surgery, University Hospital Aachen, Aachen, Germany.

Article

Publisher Item ID: S0959-8049(17)31368-0

DOI: 10.1016/j.ejca.2017.10.028

PubMed ID: 29195117

SO-VID: 7c0179b2-a832-49f8-b0da-d78a68c24a19

History

Keywords: Resection,Surgery,Metastatic colorectal cancer,Bevacizumab,Cetuximab,Conversion therapy

Data availability:

Keywords: Resection, Surgery, Metastatic colorectal cancer, Bevacizumab, Cetuximab, Conversion therapy

Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.

Read this article at

Abstract

Related collections

SICOT-J (Orthopedic surgery and traumatology)

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 166

Cited by 28